Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

SOLV

Solventum Corp

Mar 20 • 04:00PM ET

65.78

-1.36 -2.03 %

Healthcare • Medical Instruments & Supplies • USA • NYSE

Peers: SHW PPG AXTA ECL RPM VAL FUL AVNT CC ALB

| Held by: VTI VOO VB VBR RSP IVV SPY XLV IWR VHT

Index	S&P 500	P/E	7.41	EPS (ttm)	8.87	Insider Own	14.93%	Shs Outstand	173.49M	Perf Week	-1.47%
Market Cap	11.41B	Forward P/E	9.31	EPS next Y	7.07	Insider Trans	0.01%	Shs Float	147.59M	Perf Month	-10.64%
Enterprise Value	15.78B	PEG	1.08	EPS next Q	1.35	Inst Own	73.24%	Short Float	2.36%	Perf Quarter	-17.72%
Income	1.56B	P/S	1.37	EPS this Y	5.98%	Inst Trans	1.49%	Short Ratio	3.20	Perf Half Y	-11.55%
Sales	8.35B	P/B	2.26	EPS next Y	9.15%	ROA	10.82%	Short Interest	3.49M	Perf YTD	-16.99%
Book/sh	29.10	P/C	13.00	EPS next 5Y	8.62%	ROE	38.86%	52W High	88.20 -25.42%	Perf Year	-12.28%
Cash/sh	5.06	P/FCF	-	EPS past 3/5Y	4.51% 1.23%	ROIC	15.22%	52W Low	60.70 8.37%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	10.37	Sales past 3/5Y	0.79% 0.47%	Gross Margin	56.63%	Volatility	2.27% 2.66%	Perf 5Y	-
Dividend TTM	-	EV/Sales	1.89	EPS Y/Y TTM	223.24%	Oper. Margin	12.53%	ATR (14)	1.99	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.89	Sales Y/Y TTM	1.14%	Profit Margin	18.64%	RSI (14)	31.93	Recom	2.25
Dividend Gr. 3/5Y	- -	Current Ratio	1.23	EPS Q/Q	108.61%	SMA20	-5.98%	Beta	0.70	Target Price	91.91
Payout	0.00%	Debt/Eq	1.04	Sales Q/Q	-3.66%	SMA50	-12.36%	Rel Volume	2.19	Prev Close	67.14
Employees	20000	LT Debt/Eq	1.03	Earnings	Feb 26 AMC	SMA200	-12.38%	Avg Volume	1.09M	Price	65.78
IPO	Mar 26, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.03% 1.84%	Trades		Volume	2,390,622	Change	-2.03%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-26-26	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight	$97
Jan-20-26	Upgrade	Mizuho	Neutral → Outperform	$100
Dec-02-25	Upgrade	BTIG Research	Neutral → Buy	$100
Oct-01-25	Initiated	UBS	Neutral	$77
Sep-11-25	Initiated	Jefferies	Hold	$80
Jul-15-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$103
Jul-01-25	Upgrade	Argus	Hold → Buy	$90
Jun-06-25	Initiated	KeyBanc Capital Markets	Sector Weight
May-19-25	Upgrade	Piper Sandler	Neutral → Overweight	$87
Dec-04-24	Initiated	Mizuho	Neutral	$70
Oct-08-24	Initiated	Stifel	Buy	$82
Oct-07-24	Initiated	Piper Sandler	Neutral	$71
Sep-26-24	Initiated	Wolfe Research	Peer Perform
Sep-05-24	Initiated	BTIG Research	Neutral
Jun-24-24	Initiated	Argus	Hold
May-30-24	Initiated	Goldman	Sell	$54
May-10-24	Initiated	BofA Securities	Neutral	$70
Apr-10-24	Initiated	Morgan Stanley	Equal-Weight	$70
Apr-08-24	Initiated	Wells Fargo	Equal Weight	$69
Apr-02-24	Initiated	Edward Jones	Hold

Show Previous Ratings

Mar-11-26 04:05PM	Solventum to Participate in the 2026 KeyBanc Healthcare Forum (PR Newswire)
Mar-06-26 07:00AM	Middleby Appoints Glenn Eisenberg To Board of Directors (Business Wire)
Mar-05-26 11:22AM	Solventum (SOLV) Q4 2025 Adjusted Diluted EPS Reaches $1.57 on 3.5% Organic Sales Growth (Insider Monkey)
Mar-03-26 09:40AM	Solventum (SOLV) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Feb-28-26 08:05PM	Solventum Q4 Earnings Call Highlights (MarketBeat)
05:07PM	Loading…
Feb-27-26 05:07PM	Analyst Report: Solventum Corporation (Morningstar Research)
04:30PM	Solventum Beat Wall Street Earnings Estimates. The Stock Falls. (Barrons.com)
12:48PM	OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts (Zacks)
12:45PM	Solventum Stock Down Despite Q4 Earnings & Revenues Beat, Margins Down (Zacks)
08:12AM	Solventum Beat Wall Street Earnings Estimates. The Stock Is Down. (Barrons.com)
12:05AM	Solventum Corp (SOLV) Q4 2025 Earnings Call Highlights: Strong Organic Growth Amid Margin Challenges (GuruFocus.com)
Feb-26-26 05:30PM	Solventum (SOLV) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
05:30PM	Solventum (SOLV) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:17PM	Solventum's (NYSE:SOLV) Q4 CY2025 Sales Top Estimates (StockStory)
04:36PM	Solventum: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance (PR Newswire)
Feb-25-26 06:12AM	What To Expect From Solventum's (SOLV) Q4 Earnings (StockStory)
Feb-23-26 09:15AM	Curious about Solventum (SOLV) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
08:45AM	Solventum to Post Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-18-26 02:32AM	Activist Investor Nelson Peltz' Trian Fund Cut Back On This Stock In Q4, But Held Steady On GE Aerospace (Benzinga)
Feb-13-26 08:30PM	Analyst Report: Solventum Corporation (Morningstar Research)
Feb-11-26 07:46AM	Solventum Stock: Is Wall Street Bullish or Bearish? (Barchart)
Feb-10-26 07:23PM	Analyst Report: Solventum Corporation (Morningstar Research)
Feb-08-26 12:18PM	Mizuho Upgrades Solventum (SOLV), Cites Optimistic Dental Outlook, Acera Acquisition (Insider Monkey)
Feb-03-26 07:46PM	Analyst Report: Solventum Corporation (Morningstar Research)
04:05PM	Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026 (PR Newswire)
08:00AM	Here's Why Diamond Hill Large Cap Fund Added Solventum (SOLV) to Its Portfolio (Insider Monkey)
Jan-22-26 05:10AM	What You Need To Know Ahead of Solventum Earnings Release (Barchart)
Jan-20-26 05:28PM	Analyst Report: 3M Company (Morningstar Research)
Jan-13-26 11:05PM	3 Reasons SOLV is Risky and 1 Stock to Buy Instead (StockStory) -6.61%
03:30PM	Loading…
03:30PM	JPM26: ThermoFisher very positive on strategic M&A as deals expand capabilities (Pharmaceutical Technology)
Dec-30-25 09:40AM	Are Medical Stocks Lagging Solventum Corporation (SOLV) This Year? (Zacks)
Dec-24-25 01:48PM	SOLV Acquires Acera Surgical to Expand Advanced Wound Care Portfolio (Zacks)
Dec-23-25 04:05PM	Solventum Completes Acquisition of Acera Surgical (PR Newswire)
Dec-17-25 04:05PM	Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy (PR Newswire)
Dec-16-25 04:05PM	Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength (PR Newswire)
05:30AM	Is Solventum Stock Outperforming the Nasdaq? (Barchart)
Dec-10-25 08:38AM	Should You Add Solventum Corp (SOLV) to Your Portfolio? (Insider Monkey)
Dec-09-25 02:58PM	Solventum Corporation (SOLV): A Bull Case Theory (Insider Monkey)
Dec-05-25 11:53AM	BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing (Zacks)
03:35AM	These Are the 3 Hottest Stocks in the S&P 500 Heading Into the New Year. Should You Invest in Them? (Motley Fool)
Dec-04-25 11:46AM	HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency (Zacks)
Dec-01-25 06:43PM	Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity (MarketBeat)
Nov-25-25 04:05PM	Solventum to Participate in the 2025 Piper Sandler Healthcare Conference (PR Newswire)
Nov-24-25 04:38PM	Top Stock Reports for Alphabet, Roche & RTX (Zacks)
12:59PM	Solventum bolsters wound care portfolio with $850m Acera Surgical acquisition (Medical Device Network)
Nov-21-25 03:35PM	Solventum Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
01:13PM	AI Stocks Are Taking a Beating. What to Buy Instead. (Barrons.com)
05:57AM	Solventum inks $725M Acera takeover (MedTech Dive)
Nov-20-25 09:00AM	Solventum Announces Agreement to Acquire Acera Surgical (PR Newswire)
09:00AM	Solventum Announces $1 Billion Share Repurchase Program (PR Newswire)
Nov-16-25 10:31PM	Unpacking Q3 Earnings: Solventum (NYSE:SOLV) In The Context Of Other Surgical Equipment & Consumables - Diversified Stocks (StockStory)
Nov-13-25 02:00PM	BDX Unveils Portable PureWick System for On-the-Go Incontinence Care (Zacks)
01:57PM	STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics (Zacks)
08:23AM	Solventum Stock: Analyst Estimates & Ratings (Barchart)
12:32AM	5 Must-Read Analyst Questions From Solventum's Q3 Earnings Call (StockStory)
Nov-12-25 11:40AM	SOLV vs. DHR: Which Stock Is the Better Value Option? (Zacks)
Nov-11-25 12:44PM	Here's Why You Should Hold DexCom Stock in Your Portfolio for Now (Zacks)
12:00PM	Solventum (SOLV) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Nov-10-25 11:40AM	SOLV or DHR: Which Is the Better Value Stock Right Now? (Zacks)
07:03AM	Health-Insurer Stocks Drop After Trump Says ACA Funds Should Go to Public (The Wall Street Journal)
Nov-07-25 09:27AM	SOLV Q3 Deep Dive: Transformation Initiatives Drive Margin Gains Amid Tariff Headwinds (StockStory) +7.91%
08:40AM	SOLV Gains on Q3 Earnings & Sales Beat, Raises '25 EPS Outlook (Zacks)
12:07AM	Solventum Corp (SOLV) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Strategic Debt ... (GuruFocus.com)
Nov-06-25 06:00PM	Solventum (SOLV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:25PM	Solventum (SOLV) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
05:01PM	Solventum's (NYSE:SOLV) Q3: Beats On Revenue (StockStory)
04:18PM	Solventum: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Solventum Reports Third Quarter 2025 Financial Results (PR Newswire)
10:39AM	XRAY Stock Declines on Q3 Earnings Miss & Lower 2025 EPS View (Zacks)
08:35AM	Avanos Medical Gains on Q3 Earnings Beat, Raises '25 Sales View (Zacks)
08:31AM	MCK Q2 Earnings Beat, Sales Miss, '26 EPS View Up, Stock Down (Zacks)
Nov-05-25 11:54AM	Rigetti Computing to Post Q3 Earnings: What's in Store for the Stock? (Zacks)
11:01AM	CLOV Q3 Earnings Miss, Stock Falls on Raised Insurance BER View (Zacks)
10:56AM	COR Q4 Earnings & Revenues Beat Estimates, Gross Margin Improves (Zacks)
10:53AM	FMS Stock Rises as Q3 Earnings Beat Estimates, Revenues Gain Y/Y (Zacks)
09:15AM	Unveiling Solventum (SOLV) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-25 10:20PM	Solventum (SOLV) Reports Q3: Everything You Need To Know Ahead Of Earnings (StockStory)
08:39AM	Solventum to Post Q3 Earnings: Is a Beat Likely for the Stock? (Zacks)
08:39AM	DENTSPLY SIRONA to Post Q3 Earnings: What's in Store for the Stock? (Zacks)
08:38AM	Will Strong Segmental Performance Drive MCK's Top Line in Q2? (Zacks)
Nov-03-25 04:05PM	Solventum to Participate in the 2025 Stifel Healthcare Conference (PR Newswire)
Oct-31-25 01:53PM	DexCom Stock Falls Despite Q3 Earnings Beat, 2025 Revenue View Raised (Zacks)
10:18AM	SYK Stock Falls Despite Q3 Earnings & Sales Beat, '25 View Up (Zacks)
Oct-30-25 02:02PM	Avantor Stock Plunges as Q3 Earnings Miss Estimates, Revenues Down Y/Y (Zacks)
01:59PM	DaVita Stock Down Post Q3 Earnings Miss Estimates, Revenues Up Y/Y (Zacks)
01:56PM	TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y (Zacks)
12:24PM	OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands (Zacks)
12:21PM	GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised (Zacks)
10:30AM	BAX Stock Falls Following Q3 Earnings Beat & Sales Miss, '25 EPS View Down (Zacks)
10:29AM	CAH Q1 Earnings Beat Estimates, '26 EPS View Up, Stock Gains (Zacks)
10:00AM	Solventum (SOLV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 08:59AM	GE HealthCare Q3 Earnings and Revenues Beat Estimates, Net Margin Falls (Zacks)
Oct-28-25 05:14PM	Analyst Report: 3M Company (Morningstar Research)
12:10PM	Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report? (Zacks)
08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
12:04AM	3 Reasons to Avoid SOLV and 1 Stock to Buy Instead (StockStory)
Oct-27-25 10:05AM	RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised (Zacks)
09:20AM	Does GEHC Stock Deserve a Spot in Your Portfolio Ahead of Q3 Earnings? (Zacks)
Oct-24-25 08:45AM	What to Expect From Solventum's Next Quarterly Earnings Report (Barchart)

Solventum Corp. operates as a health care company. The company was founded on January 24, 2023 and is headquartered in Maplewood, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wendell Amy McBride	Director	Mar 10 '26	Buy	68.03	1,475	100,344	5,039	Mar 11 06:31 AM
Landucci Amy	Chief Information Officer	Mar 06 '26	Option Exercise	0.00	3,795	0	39,214	Mar 09 07:49 PM
Harrington Paul S	Chief Supply Chain Officer	Mar 06 '26	Option Exercise	0.00	3,300	0	19,243	Mar 09 07:49 PM
McMillan Wayde D.	Chief Financial Officer	Mar 06 '26	Option Exercise	0.00	8,802	0	46,324	Mar 09 07:49 PM
Gomez Tammy L	Chief Human Resources Officer	Mar 06 '26	Option Exercise	0.00	3,300	0	11,965	Mar 09 07:48 PM
Hanson Bryan C	Chief Executive Officer	Mar 06 '26	Option Exercise	0.00	31,907	0	134,305	Mar 09 07:48 PM
Kirberger Marcela A.	Chief Legal Affairs Officer	Mar 06 '26	Option Exercise	0.00	4,180	0	12,236	Mar 09 07:47 PM
Hanson Bryan C	Chief Executive Officer	Sep 01 '25	Option Exercise	0.00	67,261	0	128,866	Sep 02 12:49 PM
3M CO	10% Owner	Aug 15 '25	Sale	73.45	8,800,000	646,360,000	25,569,190	Aug 18 05:02 PM
COX CARRIE SMITH	Director	May 13 '25	Option Exercise	0.00	5,148	0	5,148	May 15 04:23 PM
Hanson Bryan C	Chief Executive Officer	May 13 '25	Option Exercise	0.00	34,315	0	75,108	May 15 04:23 PM
Harris Bernard A Jr	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:23 PM
Edwards Shirley Ann	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:23 PM
Wilcox Mary T	Chief Accounting Officer	May 13 '25	Option Exercise	0.00	2,375	0	2,375	May 15 04:22 PM
DeVore Susan D.	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:22 PM
ALBAN CARLOS	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:22 PM
Harrington Paul S	Chief Supply Chain Officer	May 13 '25	Option Exercise	0.00	3,959	0	11,220	May 15 04:22 PM
Wendell Amy McBride	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:22 PM
MAY KAREN J	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:21 PM
Mily Elizabeth	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,626	May 15 04:21 PM
Gomez Tammy L	Chief Human Resources Officer	May 13 '25	Option Exercise	0.00	3,959	0	6,953	May 15 04:21 PM
Wilson Darryl L.	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:21 PM
WEILAND JOHN H	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:20 PM
EISENBERG GLENN A	Director	May 13 '25	Option Exercise	0.00	3,564	0	3,564	May 15 04:20 PM
McMillan Wayde D.	Chief Financial Officer	May 13 '25	Option Exercise	0.00	9,502	0	26,410	May 15 04:20 PM
Barry Chris	Executive Vice President	May 13 '25	Option Exercise	0.00	7,918	0	7,918	May 15 04:20 PM
Landucci Amy	Chief Information Officer	May 13 '25	Option Exercise	0.00	4,421	0	20,967	May 15 04:20 PM
Kirberger Marcela A.	Chief Legal Affairs Officer	May 13 '25	Option Exercise	0.00	4,487	0	7,056	May 15 04:17 PM

Open in Screener

AXGN

Axogen Inc

Mar 20 • 04:00PM ET

30.78

-0.38 -1.22 %

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: VTI IWM VXF IWO FESM VTWO SCHA IHI VHT CPAI

Index	RUT	P/E	-	EPS (ttm)	-0.34	Insider Own	1.90%	Shs Outstand	51.90M	Perf Week	-4.82%
Market Cap	1.60B	Forward P/E	41.36	EPS next Y	0.74	Insider Trans	-33.00%	Shs Float	50.91M	Perf Month	-12.08%
Enterprise Value	1.62B	PEG	0.82	EPS next Q	0.07	Inst Own	83.18%	Short Float	5.69%	Perf Quarter	-1.94%
Income	-15.70M	P/S	7.09	EPS this Y	76.90%	Inst Trans	3.72%	Short Ratio	3.08	Perf Half Y	78.33%
Sales	225.21M	P/B	11.28	EPS next Y	45.08%	ROA	-7.38%	Short Interest	2.89M	Perf YTD	-5.96%
Book/sh	2.73	P/C	35.08	EPS next 5Y	50.42%	ROE	-13.49%	52W High	36.00 -14.50%	Perf Year	70.62%
Cash/sh	0.88	P/FCF	-	EPS past 3/5Y	20.86% 10.54%	ROIC	-8.09%	52W Low	9.22 234.02%	Perf 3Y	262.97%
Dividend Est.	-	EV/EBITDA	2453.80	Sales past 3/5Y	17.57% 14.93%	Gross Margin	74.31%	Volatility	4.43% 5.54%	Perf 5Y	43.36%
Dividend TTM	-	EV/Sales	7.19	EPS Y/Y TTM	-46.89%	Oper. Margin	-3.49%	ATR (14)	1.64	Perf 10Y	480.75%
Dividend Ex-Date	Jan 27, 2010	Quick Ratio	3.31	Sales Y/Y TTM	20.21%	Profit Margin	-6.97%	RSI (14)	44.71	Recom	1.27
Dividend Gr. 3/5Y	- -	Current Ratio	5.11	EPS Q/Q	-3081.91%	SMA20	-1.50%	Beta	1.02	Target Price	40.80
Payout	-	Debt/Eq	0.52	Sales Q/Q	21.25%	SMA50	-5.64%	Rel Volume	1.75	Prev Close	31.16
Employees	622	LT Debt/Eq	0.51	Earnings	Feb 24 BMO	SMA200	38.52%	Avg Volume	938.56K	Price	30.78
IPO	Dec 17, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	-21.17% 1.48%	Trades		Volume	1,641,942	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-19-26	Initiated	Wells Fargo	Overweight	$40
Dec-01-25	Initiated	Mizuho	Outperform	$40
Mar-17-25	Initiated	Lake Street	Buy	$30
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50

Show Previous Ratings

Mar-05-26 09:07PM	AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference (MarketBeat)
Feb-24-26 08:03PM	AxoGen, Inc. Q4 2025 Earnings Call Summary (Moby) -8.14%
02:03PM	Axogen Inc (AXGN) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
10:44AM	AxoGen Q4 Earnings Call Highlights (MarketBeat)
09:40AM	AxoGen (AXGN) Q4 Earnings Miss Estimates (Zacks)
07:32AM	Loading…
07:32AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-19-26 07:01AM	Axogen (AXGN) Benefited from Multiple Tailwinds (Insider Monkey)
Feb-17-26 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-10-26 07:00AM	Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 (GlobeNewswire)
Jan-22-26 12:42PM	Axogen Prices Upsized $124 Million Stock Offering (Benzinga)
Jan-21-26 11:18PM	Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock (GlobeNewswire)
04:09PM	Axogen Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-15-26 03:07PM	AxoGen Touts Post-BLA Growth Plan, 75%+ Gross Margin Outlook at J.P. Morgan Healthcare Conference (MarketBeat)
Jan-12-26 07:00AM	Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 (GlobeNewswire) -5.85%
07:00AM	Loading…
Dec-17-25 07:00AM	Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference (GlobeNewswire) +6.95%
Dec-03-25 08:01PM	Axogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) (GlobeNewswire) +15.97%
Nov-04-25 07:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Oct-29-25 08:15AM	AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates (Zacks) +23.06%
07:13AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-15-25 07:00AM	Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 (GlobeNewswire)
Oct-06-25 08:04AM	CLPT Expands Into Robotic System Supporting Cell and Gene Therapies (Zacks)
Sep-26-25 09:21AM	GEHC Inks License Agreement With Lantheus for Prostate Imaging Agent (Zacks)
Sep-25-25 09:24AM	Masimo Completes Divestment of Consumer Audio Business to HARMAN (Zacks)
Sep-23-25 08:21AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
Sep-12-25 09:40AM	Are Medical Stocks Lagging AxoGen (AXGN) This Year? (Zacks)
Aug-28-25 09:55AM	Does AxoGen (AXGN) Have the Potential to Rally 53.1% as Wall Street Analysts Expect? (Zacks)
Aug-27-25 08:00AM	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 04:04PM	Why Axogen Stock, Up 76% Over The Last Two Months, Just Plummeted (Investor's Business Daily) -9.04% +9.60%
10:39AM	Loading…
10:39AM	FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months (Benzinga)
06:40AM	Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft (GlobeNewswire)
Aug-20-25 09:13AM	Axogen (AXGN) Slid on a Weaker Than Expected Gross Margin (Insider Monkey)
Aug-13-25 12:08PM	Raymond James Slashes PT on Axogen (AXGN) to $20 From $21 (Insider Monkey)
Aug-12-25 09:55AM	Wall Street Analysts Predict a 76.37% Upside in AxoGen (AXGN): Here's What You Should Know (Zacks)
Aug-05-25 08:15AM	AxoGen (AXGN) Beats Q2 Earnings and Revenue Estimates (Zacks) +9.32%
07:21AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-04-25 07:10AM	Waters (WAT) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
Jul-30-25 10:00AM	Will PROCEPT BioRobotics Corporation (PRCT) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jul-29-25 04:10PM	Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
10:00AM	AxoGen (AXGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Jul-22-25 04:05PM	Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 (GlobeNewswire) +8.01% +7.34%
Jul-02-25 10:06PM	Axogen Showcases Nerve Repair Vision at Goldman Sachs (Insider Monkey)
May-28-25 08:00AM	Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference (GlobeNewswire)
May-21-25 09:35AM	AxoGen (AXGN) Loses 25.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
May-09-25 09:45AM	Solventum Stock Gains on Q1 Earnings & Revenue Beat, Margins Decline (Zacks) -9.73%
09:30AM	MCK Stock Up on Q4 Earnings Beat & Potential Surgical Biz Spin-Off (Zacks)
03:08AM	Axogen Inc (AXGN) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Progress Amid ... (GuruFocus.com)
May-08-25 08:30AM	AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -23.18%
07:28AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Reports 2025 First Quarter Financial Results (GlobeNewswire)
07:00AM	Axogen Announces Chief Financial Officer Transition (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
01:09PM	COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised (Zacks)
12:31PM	AxoGen Q1 2025 Earnings Preview (Seeking Alpha)
May-02-25 01:22PM	SYK Stock Falls Despite Q1 Earnings & Sales Beat on Lower '25 EPS View (Zacks)
01:21PM	DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins (Zacks)
Apr-24-25 08:04AM	Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025 (GlobeNewswire)
Mar-31-25 03:03PM	Stryker Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Mar-25-25 11:12AM	Axogen: LT Bullish, But Outcomes Weighted To Downside, At This Point (SeekingAlpha)
Mar-24-25 08:00AM	Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-26-25 02:03AM	Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... (GuruFocus.com)
12:27AM	Q4 2024 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:41AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance) +11.66%
07:10AM	Axogen, Inc. To Host Analyst & Investor Day on March 4th (GlobeNewswire)
07:00AM	Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-11-25 04:58PM	Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 (GlobeNewswire)
Feb-03-25 08:00AM	Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '26	Option Exercise	0.00	17,938	0	268,002	Mar 18 04:11 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '26	Sale	32.84	5,221	171,458	262,781	Mar 18 04:11 PM
Hartley Lindsey Marie	CFO	Mar 16 '26	Option Exercise	0.00	9,000	0	62,702	Mar 18 04:10 PM
Began Marc A	EVP & General Counsel	Mar 01 '26	Option Exercise	0.00	11,250	0	54,562	Mar 02 06:15 PM
Wendell Amy McBride	Director	Dec 16 '25	Option Exercise	6.91	43,684	301,963	137,510	Dec 17 04:25 PM
Wendell Amy McBride	Director	Dec 16 '25	Sale	29.31	43,684	1,280,465	93,826	Dec 17 04:25 PM
Weiler Kathy Johnson	Director	Dec 16 '25	Option Exercise	6.99	40,073	280,150	46,653	Dec 17 04:25 PM
Weiler Kathy Johnson	Director	Dec 16 '25	Sale	29.55	46,653	1,378,476	0	Dec 17 04:25 PM
Hartley Lindsey Marie	CFO	Dec 15 '25	Option Exercise	8.27	14,812	122,495	46,188	Dec 17 04:24 PM
Hartley Lindsey Marie	CFO	Dec 15 '25	Sale	29.86	14,812	442,294	31,376	Dec 17 04:24 PM
Amy McBride-Wendell	Director	Dec 16 '25	Proposed Sale	29.31	43,684	1,280,461		Dec 16 05:03 PM
KATHY WEILER	Director	Dec 16 '25	Proposed Sale	29.55	46,653	1,378,484		Dec 16 04:27 PM
LINDSEY MARIE HARTLEY	Officer	Dec 15 '25	Proposed Sale	29.86	14,812	442,294		Dec 15 05:38 PM
DALE MICHAEL D	Chief Executive Officer	Dec 10 '25	Sale	30.00	25,000	750,000	63,537	Dec 12 04:06 PM
Began Marc A	EVP & General Counsel	Dec 11 '25	Sale	30.00	13,222	396,660	18,285	Dec 12 04:05 PM
MARC BEGAN	Officer	Dec 11 '25	Proposed Sale	30.00	13,222	396,660		Dec 11 04:08 PM
DALE MICHAEL D	Chief Executive Officer	Dec 09 '25	Sale	31.21	61,463	1,918,137	88,537	Dec 10 05:21 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Option Exercise	8.73	25,108	219,223	25,108	Dec 10 05:20 PM
TYNDALL JOSEPH A.	Director	Dec 09 '25	Sale	30.98	25,108	777,771	0	Dec 10 05:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Dec 09 '25	Sale	31.21	19,517	609,087	241,132	Dec 10 05:20 PM
Kemp Jens	Chief Marketing Officer	Dec 09 '25	Sale	31.21	8,156	254,532	46,030	Dec 10 05:20 PM
Began Marc A	EVP & General Counsel	Dec 09 '25	Sale	31.21	9,278	289,548	31,507	Dec 10 05:19 PM
THOMAS PAUL	Director	Dec 09 '25	Sale	29.61	21,399	633,710	13,528	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Option Exercise	6.30	11,891	74,913	25,032	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Option Exercise	6.30	8,545	53,834	21,686	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 08 '25	Sale	31.24	23,693	740,203	13,141	Dec 10 05:19 PM
JOHNSON JOHN	Director	Dec 09 '25	Sale	29.98	21,686	650,190	0	Dec 10 05:19 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Option Exercise	13.82	25,000	345,400	45,763	Dec 10 05:18 PM
Hartley Lindsey Marie	CFO	Dec 08 '25	Sale	31.56	14,387	454,005	31,376	Dec 10 05:18 PM
MICHAEL DALE	Officer	Dec 10 '25	Proposed Sale	30.00	25,000	750,000		Dec 10 04:19 PM
PAUL THOMAS	Director	Dec 09 '25	Proposed Sale	29.61	21,399	633,710		Dec 09 04:40 PM
JOSEPH A TYNDALL	Director	Dec 09 '25	Proposed Sale	30.98	25,108	777,771		Dec 09 04:39 PM
JOHN H JOHNSON	Director	Dec 09 '25	Proposed Sale	29.98	21,686	650,186		Dec 09 04:05 PM
JOHN H JOHNSON	Director	Dec 08 '25	Proposed Sale	31.24	23,693	740,207		Dec 08 06:21 PM
LINDSEY MARIE HARTLEY	Officer	Dec 08 '25	Proposed Sale	31.56	14,387	454,009		Dec 08 04:32 PM
Burke William P. Mr.	Director	Nov 10 '25	Option Exercise	8.14	19,227	156,508	19,327	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Option Exercise	8.14	3,591	29,231	3,691	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 10 '25	Sale	24.01	19,227	461,640	100	Nov 13 04:31 PM
Burke William P. Mr.	Director	Nov 11 '25	Sale	24.02	3,591	86,249	100	Nov 13 04:31 PM
WILLIAM BURKE	Director	Nov 11 '25	Proposed Sale	24.00	3,591	86,184		Nov 12 07:05 AM
WILLIAM BURKE	Director	Nov 10 '25	Proposed Sale	23.57	19,227	453,180		Nov 10 04:30 PM
Burke William P. Mr.	Director	Nov 05 '25	Option Exercise	8.14	11,431	93,048	11,531	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Option Exercise	8.14	5,347	43,525	5,447	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 05 '25	Sale	24.05	11,431	274,893	100	Nov 07 04:52 PM
Burke William P. Mr.	Director	Nov 06 '25	Sale	24.01	5,347	128,371	100	Nov 07 04:52 PM
WILLIAM BURKE	Director	Nov 06 '25	Proposed Sale	23.38	5,347	125,013		Nov 06 04:20 PM
WILLIAM BURKE	Director	Nov 05 '25	Proposed Sale	23.77	11,431	271,715		Nov 05 04:20 PM
Burke William P. Mr.	Director	Oct 29 '25	Option Exercise	7.21	40,235	289,911	20,536	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Option Exercise	7.04	18,248	128,466	18,348	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 29 '25	Sale	20.55	40,235	827,013	100	Oct 31 04:09 PM
Burke William P. Mr.	Director	Oct 30 '25	Sale	23.00	18,248	419,704	100	Oct 31 04:09 PM
WILLIAM BURKE	Director	Oct 30 '25	Proposed Sale	22.25	18,248	406,018		Oct 30 04:16 PM
WILLIAM BURKE	Director	Oct 29 '25	Proposed Sale	18.08	36,162	653,809		Oct 29 04:25 PM
Burke William P. Mr.	Director	Oct 22 '25	Sale	18.02	1,457	26,252	100	Oct 24 04:09 PM
Burke William P. Mr.	Director	Oct 22 '25	Proposed Sale	18.02	1,457	26,252		Oct 22 04:41 PM
Burke William P. Mr.	Director	Oct 06 '25	Sale	18.00	736	13,249	1,557	Oct 07 05:18 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	14,571	265,283	2,293	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 03 '25	Sale	18.21	7,600	138,367	0	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	7,620	137,200	16,864	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 02 '25	Sale	18.01	2,400	43,224	7,600	Oct 06 04:54 PM
Burke William P. Mr.	Director	Oct 06 '25	Proposed Sale	18.00	736	13,249		Oct 06 04:54 PM
WILLIAM BURKE	Director	Oct 03 '25	Proposed Sale	17.88	14,937	267,074		Oct 03 04:36 PM
Burke William P. Mr.	Director	Oct 03 '25	Proposed Sale	18.25	11,307	206,317		Oct 03 04:29 PM
Burke William P. Mr.	Director	Oct 02 '25	Proposed Sale	18.01	2,400	43,224		Oct 02 04:24 PM
WILLIAM BURKE	Director	Oct 02 '25	Proposed Sale	17.87	7,620	136,169		Oct 02 04:21 PM
DeVinney Erick Wayne	Chief Innovation Officer	Sep 16 '25	Sale	16.29	1,137	18,522	220,649	Sep 16 05:22 PM
Weiler Kathy Johnson	Director	Jun 09 '25	Sale	10.61	4,073	43,215	6,580	Jun 11 04:27 PM
Levine Alan M	Director	Jun 09 '25	Sale	10.61	4,073	43,215	36,743	Jun 11 04:26 PM
Wendell Amy McBride	Director	Jun 09 '25	Sale	10.61	4,073	43,215	93,826	Jun 11 04:26 PM
Burke William P. Mr.	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,484	Jun 11 04:25 PM
NEELS GUIDO J	Director	Jun 09 '25	Sale	10.61	4,073	43,215	86,743	Jun 11 04:24 PM
JOHNSON JOHN	Director	Jun 09 '25	Sale	10.61	4,073	43,215	24,943	Jun 11 04:23 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Option Exercise	6.56	11,586	75,952	26,931	Jun 11 04:22 PM
TYNDALL JOSEPH A.	Director	Jun 10 '25	Sale	10.72	26,931	288,700	0	Jun 11 04:22 PM
JOSEPH A TYNDALL	Director	Jun 10 '25	Proposed Sale	10.72	26,931	288,814		Jun 10 05:41 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Option Exercise	6.30	12,850	80,955	35,407	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Sale	11.20	20,062	224,694	15,345	May 23 04:32 PM
TYNDALL JOSEPH A.	Director	May 19 '25	Sale	11.63	2,525	29,366	22,557	May 23 04:12 PM
TYNDALL JOSEPH A.	Director	May 22 '25	Proposed Sale	11.15	32,339	360,580		May 22 05:14 PM

SOLV

Solventum Corp

AXGN

Axogen Inc

Upgrade your FINVIZ experience